NYSEAMERICAN:CANF - Can-Fite BioPharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 107.47 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.41
▼ -0.07 (-2.82%)
1 month | 3 months | 12 months
Get New Can-Fite BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CANF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CANF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.00
▲ +107.47% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Can-Fite BioPharma in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 107.47% upside from the last price of $2.41.

Buy

The current consensus among 2 polled investment analysts is to buy stock in Can-Fite BioPharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/15/2021Alliance Global PartnersInitiated CoverageBuy
i
2/26/2021HC WainwrightReiterated RatingBuy
i
Rating by V. Bernardino at HC Wainwright
7/2/2020HC WainwrightReiterated RatingBuy$5.00
i
Rating by Vernon Bernardino at HC Wainwright
5/18/2020HC WainwrightReiterated RatingBuy$5.00
i
Rating by Vernon Bernardino at HC Wainwright
2/24/2020HC WainwrightReiterated RatingBuy$5.00
i
Rating by Vernon Bernardino at HC Wainwright
10/31/2019HC WainwrightReiterated RatingBuy ➝ Positive$3.00 ➝ $5.00
i
Rating by Vernon Bernardino at HC Wainwright
9/24/2019HC WainwrightLower Price TargetBuy$3.00
i
Rating by V. Bernardino at HC Wainwright
3/27/2019HC WainwrightReiterated RatingBuy
i
Rating by Jason Kolbert at HC Wainwright
3/26/2019HC WainwrightReiterated RatingBuy
i
Rating by V. Bernardino at HC Wainwright
10/31/2018HC WainwrightSet Price TargetBuy$8.00
i
Rating by Jason Kolbert at HC Wainwright
9/6/2018HC WainwrightSet Price TargetBuy$8.00
i
Rating by Jason Kolbert at HC Wainwright
8/31/2018HC WainwrightSet Price TargetBuy$8.00
i
Rating by Jason Kolbert at HC Wainwright
8/22/2018HC WainwrightSet Price TargetBuy$8.00
i
Rating by Jason Kolbert at HC Wainwright
8/6/2018HC WainwrightSet Price TargetBuy$8.00
i
Rating by Jason Kolbert at HC Wainwright
6/15/2018Maxim GroupReiterated RatingHold
i
Rating by Jason Kolbert at Maxim Group
6/13/2018HC WainwrightReiterated RatingBuy$8.00
i
Rating by J. Kolbert at HC Wainwright
3/9/2018Maxim GroupReiterated RatingBuy ➝ Hold$7.00
i
Rating by Jason Kolbert at Maxim Group
2/1/2018HC WainwrightReiterated RatingBuy$6.00
i
1/8/2018Maxim GroupSet Price TargetBuy$7.00
i
Rating by Jason Kolbert at Maxim Group
12/18/2017Maxim GroupSet Price TargetBuy$7.00
i
Rating by Jason Kolbert at Maxim Group
10/31/2017HC WainwrightReiterated RatingBuy
i
Rating by R. Selvaraju at HC Wainwright
10/31/2017HC WainwrightSet Price TargetBuy$6.00
i
Rating by Ram Selvaraju at HC Wainwright
10/30/2017Maxim GroupSet Price TargetBuy$7.00
i
Rating by Jason Kolbert at Maxim Group
10/17/2017Maxim GroupSet Price TargetBuy$7.00
i
Rating by Jason Kolbert at Maxim Group
9/18/2017Maxim GroupReiterated RatingBuy$7.00
i
Rating by Jason McCarthy at Maxim Group
9/1/2017Maxim GroupReiterated RatingBuy$7.00
i
Rating by Jason McCarthy at Maxim Group
8/23/2017Maxim GroupSet Price TargetBuy$7.00
i
Rating by Jason McCarthy at Maxim Group
8/11/2017Maxim GroupInitiated CoverageBuy$7.00
i
8/10/2017HC WainwrightSet Price TargetBuy$6.00
i
Rating by Ram Selvaraju at HC Wainwright
10/19/2016Roth CapitalReiterated RatingBuy
i
10/18/2016Roth CapitalReiterated RatingBuy
i
Rating by S. Yaniv at Roth Capital
8/29/2016Rodman & RenshawInitiated CoverageBuy$6.00
i
(Data available from 6/16/2016 forward)
Can-Fite BioPharma logo
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah-Tikva, Israel.
Read More

Today's Range

Now: $2.41
$2.30
$2.50

50 Day Range

MA: $1.85
$1.78
$1.97

52 Week Range

Now: $2.41
$1.51
$4.39

Volume

1,228,268 shs

Average Volume

2,442,747 shs

Market Capitalization

$41.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Can-Fite BioPharma?

The following Wall Street analysts have issued stock ratings on Can-Fite BioPharma in the last twelve months: Alliance Global Partners, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for CANF.

What is the current price target for Can-Fite BioPharma?

1 Wall Street analysts have set twelve-month price targets for Can-Fite BioPharma in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 107.5%. HC Wainwright has the highest price target set, predicting CANF will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Can-Fite BioPharma in the next year.
View the latest price targets for CANF.

What is the current consensus analyst rating for Can-Fite BioPharma?

Can-Fite BioPharma currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CANF will outperform the market and that investors should add to their positions of Can-Fite BioPharma.
View the latest ratings for CANF.

What other companies compete with Can-Fite BioPharma?

How do I contact Can-Fite BioPharma's investor relations team?

Can-Fite BioPharma's physical mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The biotechnology company's listed phone number is +972-3-9241114 and its investor relations email address is [email protected] The official website for Can-Fite BioPharma is www.canfite.co.il.